| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Lincomycin hydrochloride anhydrous targets the bacterial ribosome, specifically the 23S rRNA of the 50S ribosomal subunit. By binding to this site, it inhibits the transpeptidase reaction, which is essential for peptide bond formation during protein synthesis. This inhibition of protein synthesis leads to the bacteriostatic effect of the antibiotic. The anhydrous form has a potency equivalent to not less than 790 µg of lincomycin per mg.
|
|---|---|
| ln Vitro |
In vitro, lincomycin hydrochloride anhydrous demonstrates antibacterial activity against a wide variety of bacteria, including Staphylococcal, Streptococcal, and Bacteroides fragilis. It is a narrow-spectrum antibiotic effective against Gram-positive bacteria. Its minimum inhibitory concentrations (MICs) against susceptible strains are well-documented.
|
| ln Vivo |
In vivo, lincomycin hydrochloride anhydrous is used to treat infections caused by Staphylococcus, Streptococcus, and Bacteroides fragilis. Its clinical efficacy is well-established for these indications. It is used in the treatment of serious infections caused by susceptible bacteria.
|
| Enzyme Assay |
Non-cell-based assays for lincomycin hydrochloride anhydrous are not typical, as its mechanism of action involves binding to the ribosome.
|
| Cell Assay |
Cellular assays for lincomycin hydrochloride anhydrous are performed using standard broth microdilution or agar dilution methods to determine the minimum inhibitory concentration (MIC) against bacterial strains. Bacteria are cultured in appropriate medium and treated with lincomycin at various concentrations. Bacterial growth is assessed by optical density measurement or colony counting after overnight incubation.
|
| Animal Protocol |
In vivo animal models for lincomycin hydrochloride anhydrous would typically involve the use of mice infected with a pathogenic bacterium. The compound is administered, and its efficacy is assessed by measuring survival rates and bacterial burden.
|
| ADME/Pharmacokinetics |
Lincomycin hydrochloride anhydrous has a molecular weight of 443.0 g/mol and a molecular formula of C18H34N2O6S·HCl. It is soluble in water (89 mg/mL) and DMSO (89 mg/mL). It has a potency of ≥790 µg/mg. It is typically administered orally or parenterally. Detailed PK parameters are not extensively detailed.
|
| Toxicity/Toxicokinetics |
Lincomycin hydrochloride anhydrous has a well-established safety profile from its clinical use. Common side effects include gastrointestinal disturbances. The compound is intended for research use only and is not for human consumption in a research context.
|
| References |
|
| Additional Infomation |
Lincomycin hydrochloride is the hydrochloride form of lincomycin, a lincosamide antibiotic originally discovered from the actinomycete Streptomyces lincolnensis. It is active against Gram-positive cocci and anaerobic bacteria. It is an antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used to treat infections caused by Staphylococcus, Streptococcus, and Bacteroides fragilis.
Lincomycin hydrochloride anhydrous is the anhydrous form of lincomycin hydrochloride. It is a narrow-spectrum antibiotic effective against Gram-positive bacteria. It binds to the 23S rRNA of the 50S ribosomal subunit and inhibits protein synthesis. It has the CAS number 859-18-7 and is supplied for research purposes. |
| Molecular Formula |
C18H35CLN2O6S
|
|---|---|
| Molecular Weight |
442.9983
|
| Exact Mass |
442.19
|
| CAS # |
859-18-7
|
| Related CAS # |
Lincomycin hydrochloride monohydrate;7179-49-9
|
| PubChem CID |
6419944
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
646.8ºC at 760 mmHg
|
| Melting Point |
156-158ºC
|
| Flash Point |
345ºC
|
| LogP |
0.273
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
28
|
| Complexity |
499
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
[C@H]([C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)([C@H](O)C)NC([C@H]1N(C)C[C@H](CCC)C1)=O.Cl
|
| InChi Key |
POUMFISTNHIPTI-DKEHCADZSA-N
|
| InChi Code |
InChI=1S/C18H34N2O6S.ClH/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4;/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25);1H/t9-,10-,11+,12-,13+,14+,15-,16-,18-;/m1./s1
|
| Chemical Name |
(2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3S,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2573 mL | 11.2867 mL | 22.5734 mL | |
| 5 mM | 0.4515 mL | 2.2573 mL | 4.5147 mL | |
| 10 mM | 0.2257 mL | 1.1287 mL | 2.2573 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
